NEWPORT BEACH, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and full year 2019 financial results and provide a

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4 NEWPORT BEACH, Calif. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach

Q4 2019 net revenue estimated between $18.5 and $19.5 million ; increased from $13.2 million in Q3 2019 Completed Q4 2019 with over 3,500 purchasing accounts; increased from over 2,000 at end of Q3 2019 Year-end 2019 cash, cash equivalents and short-term investments balance of $129.8 million